calorie intake on semaglutide Semaglutide: Optimal Range Ozempic: 10 Things to Know

No confirmed causal link between retatrutide and joint pain exists, as the drug remains unlicensed and its full side-effect profile is not yet established through post-marketing surveillance

Texas residents can schedule virtual visits in minutes

What is a compounded GLP-1

Thrive through every stage

Treatment for type 2 diabetes

placebo INDIANAPOLIS, May 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes